You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Genosity will combine its Integrated Genomic Toolkit with Israel-based Igentify's genetic counseling software, which both firms will comarket.
The company has been relentless in scaling its capabilities to offer COVID-19 testing solutions in the face of the coronavirus pandemic.
The company performed 84,067 total tests in Q3 but missed the analysts' average estimates on the top and bottom lines.
The skin cancer diagnostics company said it delivered 7 percent more DecisionDx-Melanoma test results in Q3 2020 than in the previous year's third quarter.
The startup aims to combine its microfluidic platform with a circulating tumor DNA-based assay offered by a potential partner and launch the test by 2022.
The approach, which is developed for both Illumina and nanopore sequencing, had high sensitivity and specificity for identifying bacteria and fungi.
The British bioinformatics firm expects to move into somatic cancer and wellness programs, as well as widen its geographic footprint.
The test is designed to measure the expression of IFI27, a gene strongly correlated with disease progression in influenza and COVID-19.
The Chinese company reported revenues of RMB112.0 million ($16.5 million), driven by growth in sales of both its LDT services and IVD products.
Revenues and earnings were down year over year, but the company still beat the consensus Wall Street estimates on the top and bottom lines.
The firms said they are collaborating to facilitate genetic testing to support early diagnosis of GM1, a rare monogenic recessive lysosomal storage disease.
The test will use a blood-based biopsy to detect patients with BRCA1, BRCA2, and/or ATM alterations in metastatic castration-resistant prostate cancer.
BioFire has submitted a 39-target test to the US Food and Drug Administration. OpGen also has a test in development.
The rapid, point-of-care test will be designed to help healthcare providers distinguish between influenza and SARS-CoV-2 in a single sample.
The company plans to show new data for its Signatera oncology test at three upcoming conferences this year, including in breast cancer and bladder cancer.
The tests are covered when the patient has a personal history of melanoma and the test has demonstrated clinical and analytical validity.
The company's system revenues were up 28 percent to $19.5 million and consumables revenues dropped 12 percent to $11.8 million.
The firm generated $68.7 million in revenues compared to $56.5 million in Q3 2019 and exceeded the consensus Wall Street estimate.
Product revenues increased 39 percent year over year to $93.3 million, while license and other revenues were down 56 percent to $4.9 million.
The liquid biopsy's firm's net loss rose significantly year over year, but it beat the top line consensus Wall Street estimate, with total revenues of $74.6 million for the quarter.
Bloomberg reports AstraZeneca may conduct another study of its candidate SARS-CoV-2 vaccine after dosing error.
Moderna is applying for an Emergency Use Authorization for its coronavirus vaccine, according to the New York Times.
The National Health Service is to conduct a trial of Grail's blood-based screening test for cancer.
In PLOS this week: somatic mutation patterns of glioblastomas among Lebanese patients, phenome-wide study using UK Biobank data, and more.